S1300: A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit From Crizotinib Monotherapy
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Crizotinib (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 06 Dec 2017 Status changed from recruiting to suspended.
- 10 Jun 2017 Biomarkers information updated
- 19 Nov 2014 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.